Valproato semisodico [Spanish] en es it fr

Category

Valproato_semisodico_[Spanish]
add to favotites goo dig stu tec squ mys
fac del pro twi yah mya far


Valproato semisodico [Spanish] Brand names, Valproato semisodico [Spanish] Analogs

Valproato semisodico [Spanish] Brand Names Mixture

  • No information avaliable

Valproato semisodico [Spanish] Chemical_Formula

C8H16O2

Valproato semisodico [Spanish] RX_link

http://www.rxlist.com/cgi/generic2/depakene.htm

Valproato semisodico [Spanish] fda sheet

Valproato semisodico [Spanish] msds (material safety sheet)

Valproato_semisodico_[Spanish] MSDS

Valproato semisodico [Spanish] Synthesis Reference

Oberreit, Ber.29, 1998 (1896)

Valproato semisodico [Spanish] Molecular Weight

144.211 g/mol

Valproato semisodico [Spanish] Melting Point

120 - 130 oC

Valproato semisodico [Spanish] H2O Solubility

Slightly soluble (1.3 mg/mL)

Valproato semisodico [Spanish] State

Solid

Valproato semisodico [Spanish] LogP

2.549

Valproato semisodico [Spanish] Dosage Forms

Capsule (250 mg); Syrup (250 mg drug/5mL syrup)

Valproato semisodico [Spanish] Indication

For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.

Valproato semisodico [Spanish] Pharmacology

Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.

Valproato semisodico [Spanish] Absorption

Rapid absorption from gastrointestinal tract.

Valproato semisodico [Spanish] side effects and Toxicity

Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.

Valproato semisodico [Spanish] Patient Information

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Valproato semisodico [Spanish] Organisms Affected

Humans and other mammals